Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer

Y. Okugawa, C. Miki, Y. Toiyama, H. Yasuda, T. Yokoe, S. Saigusa, J. Hiro, K. Tanaka, Y. Inoue, M. Kusunoki

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Background:Interleukin-6 (IL-6) binds both the membrane and soluble forms of the IL-6 receptor (sIL-6R), which induces a complex with gp130, and proliferation of tumour cells. The aim of this study is to clarify the relationship between tumoral sIL-6R expression and disease progression in colorectal cancer patients.Methods:We measured tissue concentrations of sIL-6R in tumour and normal mucosa from 161 colorectal cancer patients undergoing surgery, and in supernatants from colon cancer cell lines. The expression of IL-6, IL-6R and gp130 was evaluated by immunohistochemical analysis.Results:Loss of tumour expression of sIL-6R as defined by sIL-6R Ca/N ratio 1.0 was significantly associated with factors reflecting disease progression, and was an independent prognostic factor not only in all the patients in this study, but also in the patients with curative intent. Colon cancer cell lines produced sIL-6R in vitro, and the production of sIL-6R in cancer cell lines was stimulated by cytokine stimulation. Immunohistochemistry revealed that loss of tumour expression of sIL-6R was significantly inversely correlated with intense IL-6 expression in the cytoplasm of cancer cells. In addition, tumoral IL-1Β expression was significantly correlated with sIL-6R expression.Conclusion:Loss of tumour expression of sIL-6R is associated with colorectal cancer disease progression.

Original languageEnglish
Pages (from-to)787-795
Number of pages9
JournalBritish Journal of Cancer
Volume103
Issue number6
DOIs
Publication statusPublished - 07-09-2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer'. Together they form a unique fingerprint.

Cite this